Replaces Prod. #: ALX-380-015
Antiviral and immunosuppressive activity. Clinically useful antipsoriatic agent. Mycophenolic acid prodrugs are effective in rheumatoid arthritis and for the prevention of organ transplant rejection. Mechanism of action is inhibition of inosine-5'-monophosphate dehydrogenase.
Product Details
Alternative Name: | 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexanoic acid |
|
Formula: | C17H20O6 |
|
MW: | 320.3 |
|
Source: | Isolated from Penicillium brevi-compactum |
|
CAS: | 24280-93-1 |
|
RTECS: | MP8050000 |
|
Purity: | ≥98% (HPLC) |
|
Appearance: | White solid. |
|
Solubility: | Soluble in DMSO (clear colorless solution at 50 mg/ml) or 100% ethanol. |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Store solutions at -20°C for up to 3 months. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil: A. C Allison et al.; Immunol. Rev.
136, 5 (1993),
Abstract;
The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients: R.D. Ensley et al.; Transplantation
56, 75 (1993),
Abstract;
Therapy of rheumatoid arthritis with mycophenolate mofetil: R. Goldblum; Clin. Exp. Rheumatol.
11 Suppl 8, S117 (1993),
Abstract;
Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety: W.W. Epinette et al.; J. Am. Acad. Dermatol.
17, 962 (1987),
Abstract;